ReviewFEMS yeast research2015
Candida glabrata: new tools and technologies-expanding the toolkit.
Review in FEMS yeast research, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 28 citations in OpenAlex.
- Prevalence, drug resistance and genetic diversity ofMycology · 2025Article
- Design, Biological Evaluation, and Computer-Aided Analysis of Dihydrothiazepines as Selective Antichlamydial Agents.Journal of medicinal chemistry · 2023Article
- Mass spectrometry in research laboratories and clinical diagnostic: a new era in medical mycology.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2022Review
- Fluorescent toys 'n' tools lighting the way in fungal research.FEMS microbiology reviews · 2021Article
- Review
- Rapid proliferation due to better metabolic adaptation results in full virulence of a filament-deficient Candida albicans strain.Nature communications · 2021Article
- Functional Characterization of a Novel Oxidative Stress Protection Protein in the Pathogenic YeastFrontiers in genetics · 2020Article
- CRISPR-Based Genetic Manipulation ofFrontiers in genome editing · 2020Review
- CgSTE11 mediates cross tolerance to multiple environmental stressors in Candida glabrata.Scientific reports · 2019Article
- Review
- Genome engineering in the yeast pathogen Candida glabrata using the CRISPR-Cas9 system.Scientific reports · 2016Article
- Development of a Candida glabrata dominant nutritional transformation marker utilizing the Aspergillus nidulans acetamidase gene (amdS).FEMS yeast research · 2016Article
- The birth of a deadly yeast: tracing the evolutionary emergence of virulence traits in Candida glabrata.FEMS yeast research · 2016Review
- Potassium Uptake Mediated by Trk1 Is Crucial for Candida glabrata Growth and Fitness.PloS one · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
In recent years, there has been a noticeable rise in fungal infections related to non-albicans Candida species, including Candida glabrata which has both intrinsic resistance to and commonly acquired resistance to azole antifungals. Phylogenetically, C. glabrata is more closely related to the mostly non-pathogenic model organism Saccharomyces cerevisiae than to other Candida species. Despite C. glabrata's designation as a pathogen by Wickham in 1957, relatively little is known about its mechanism of virulence. Over the past few years, technology to analyse the molecular basis of infection has developed rapidly, and here we briefly review the major advances in tools and technologies available to explore and investigate the virulence of C. glabrata that have occurred over the past decade.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.